Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy

(2018) Theodoros Karantanos et al.   BLOOD REVIEWS

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

(2018) Roberta Zappasodi et al.   CANCER CELL

Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients

(2018) C. Yuan et al.   Clinical & Translational Oncology

A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors

(2018) Bhanu Prasad Venkatesulu et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials

(2018) Hossein Maymani et al.   LUNG CANCER

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect

(2018) María E. Rodríguez-Ruiz et al.   TRENDS IN IMMUNOLOGY

Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma

(2018) Yang An et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

(2018) Danielle Benedict Sacdalan et al.   OncoTargets and Therapy

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

(2018) Priyanka B. Subrahmanyam et al.   Journal for ImmunoTherapy of Cancer

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma

(2018) John E. Mullinax et al.   Frontiers in Oncology

Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

(2018) Tímea Balatoni et al.   PATHOLOGY & ONCOLOGY RESEARCH

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer

(2018) Nataly Manjarrez-Orduño et al.   Frontiers in Immunology

Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

(2018) Won Jin Ho et al.   Journal for ImmunoTherapy of Cancer

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

(2018) Aixa E. Soyano et al.   Journal for ImmunoTherapy of Cancer

Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma

(2017) Yoshiko Takeuchi et al.   INTERNATIONAL IMMUNOLOGY

Early Lymphocyte Recovery and Outcome in Osteosarcoma

(2017) Lynn Lee et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Neutrophils in cancer: prognostic role and therapeutic strategies

(2017) Alberto Ocana et al.   Molecular Cancer

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Predictors of responses to immune checkpoint blockade in advanced melanoma

(2017) N. Jacquelot et al.   Nature Communications

Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors

(2017) Adam Diehl et al.   Oncotarget

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

(2017) Alexandra Snyder et al.   PLOS MEDICINE

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

(2017) Jun Zhou et al.   Cancer Immunology Research

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

(2017) Cristina Maccalli et al.   OncoImmunology

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

(2017) Christian Klein et al.   OncoImmunology

Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy

(2017) Yutaka Shiraishi et al.   RADIOTHERAPY AND ONCOLOGY

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

(2016) Ajjai Alva et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy

(2016) K.-S. Le et al.   CANCER RESEARCH

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

(2016) A. Martens et al.   CLINICAL CANCER RESEARCH

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas

(2016) M. S. Merchant et al.   CLINICAL CANCER RESEARCH

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis

(2016) Nicolas Jacquelot et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy

(2016) Lewis Zhichang Shi et al.   Nature Communications

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation

(2016) G. C. Sim et al.   Cancer Immunology Research

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

(2016) J. Weber et al.   Cancer Immunology Research

ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients

(2015) O. Trédan et al.   ANNALS OF ONCOLOGY

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

(2015) Dalil Hannani et al.   CELL RESEARCH

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

(2015) C. Gebhardt et al.   CLINICAL CANCER RESEARCH

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

(2015) Kevin C. Conlon et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells

(2015) Rafael Carretero et al.   NATURE IMMUNOLOGY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

(2015) B. M. Carreno et al.   SCIENCE

Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models

(2015) P. R. Rhode et al.   Cancer Immunology Research

The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy

(2015) T. A. Waldmann   Cancer Immunology Research

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay

(2015) E. Verronèse et al.   OncoImmunology

Characterization of thein vivoimmune network of IDO, tryptophan metabolism, PD-L1, andCTLA-4in circulating immune cells in melanoma

(2015) I Chevolet et al.   OncoImmunology

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

(2015) Michael A. Postow et al.   Journal for ImmunoTherapy of Cancer

Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma

(2014) B. Schilling et al.   ANNALS OF ONCOLOGY

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

(2014) L. Robert et al.   CLINICAL CANCER RESEARCH

Molecular Profiling Reveals a Tumor-Promoting Phenotype of Monocytes and Macrophages in Human Cancer Progression

(2014) Manesh Chittezhath et al.   IMMUNITY

The Alteration and Clinical Significance of Th1/Th2/Th17/Treg Cells in Patients with Multiple Myeloma

(2014) Ping Feng et al.   INFLAMMATION

Lymphopenia Association With Gross Tumor Volume and Lung V5 and Its Effects on Non-Small Cell Lung Cancer Patient Outcomes

(2014) Chad Tang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The Common  -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands

(2014) A. L. Kinter et al.   JOURNAL OF IMMUNOLOGY

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

(2014) Arnoud J. Templeton et al.   JNCI-Journal of the National Cancer Institute

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response

(2014) P. Kvistborg et al.   Science Translational Medicine

Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients

(2014) E. Cha et al.   Science Translational Medicine

Quantifying and Predicting the Effect of Exogenous Interleukin-7 on CD4+T Cells in HIV-1 Infection

(2014) Rodolphe Thiébaut et al.   PLoS Computational Biology

Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression

(2014) liufu deng et al.   OncoImmunology

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

(2013) J. Delyon et al.   ANNALS OF ONCOLOGY

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

(2013) I Ray-Coquard et al.   BRITISH JOURNAL OF CANCER

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

(2013) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality

(2013) S. Kalathil et al.   CANCER RESEARCH

Increased circulating Lin−/lowCD33+HLA-DR−myeloid-derived suppressor cells in hepatocellular carcinoma patients

(2013) Peng Shen et al.   HEPATOLOGY RESEARCH

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2013) Ken Ohmachi et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-7 Modulates In Vitro and In Vivo Human Memory T Regulatory Cell Functions through the CD39/ATP Axis

(2013) M. Younas et al.   JOURNAL OF IMMUNOLOGY

Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2

(2013) T. Carmenate et al.   JOURNAL OF IMMUNOLOGY

Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma

(2013) Michela de Martino et al.   JOURNAL OF UROLOGY

Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma

(2013) Danielle Shafer et al.   LEUKEMIA RESEARCH

Human CD4+CD25+ Regulatory T Cells Are Sensitive to Low Dose Cyclophosphamide: Implications for the Immune Response

(2013) Daniel Heylmann et al.   PLoS One

De Novo Malignancies Following Liver Transplantation: Results From a Multicentric Study in Central and Southern Italy, 1990–2008

(2013) G.M. Ettorre et al.   TRANSPLANTATION PROCEEDINGS

Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy

(2013) D. Ng Tang et al.   Cancer Immunology Research

The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: A study of 826 cases from the International Peripheral T-cell Lymphoma Project

(2012) Zdravko Mitrovic et al.   AMERICAN JOURNAL OF HEMATOLOGY

Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation

(2012) M.-A. Perales et al.   BLOOD

TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma

(2012) Pengyuan Yang et al.   CANCER CELL

ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells

(2012) J. Faget et al.   CANCER RESEARCH

Impaired IFN-  Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression

(2012) V. Sisirak et al.   CANCER RESEARCH

Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells

(2012) C. Conrad et al.   CANCER RESEARCH

Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer

(2012) Ugo De Giorgi et al.   Clinical Breast Cancer

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

CD4 lymphopenia to identify end-of-life metastatic cancer patients

(2012) Julien Péron et al.   EUROPEAN JOURNAL OF CANCER

Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome

(2012) Olivier Trédan et al.   EUROPEAN JOURNAL OF CANCER

Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients

(2012) Yamila S Rocca et al.   Innate Immunity

Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells

(2012) R. N. Ramos et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

(2012) Wenshi Wang et al.   Journal of Translational Medicine

Lymphopenia is an Independent Predictor of Inferior Outcome in Clear Cell Renal Carcinoma

(2012) Sunil Saroha et al.   JOURNAL OF UROLOGY

T-cell receptor diversity prevents T-cell lymphoma development

(2012) S Newrzela et al.   LEUKEMIA

Primary Sjögren’s syndrome and B-non-Hodgkin lymphoma: role of CD4+ T lymphocytopenia

(2012) Faten Ismail et al.   RHEUMATOLOGY INTERNATIONAL

Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival

(2012) Michel Morre et al.   Targeted Oncology

Targeting regulatory T cells

(2012) Christine Ménétrier-Caux et al.   Targeted Oncology

Differential macrophage programming in the tumor microenvironment

(2012) Brian Ruffell et al.   TRENDS IN IMMUNOLOGY

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients

(2012) Manuarii Manuel et al.   OncoImmunology

Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma

(2011) Tomohiro Aoki et al.   ANNALS OF HEMATOLOGY

Natural Innate and Adaptive Immunity to Cancer

(2011) Matthew D. Vesely et al.   Annual Review of Immunology

IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood

(2011) M. C. Sneller et al.   BLOOD

Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy

(2011) N. Cézé et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer

(2011) S. I. Labidi-Galy et al.   CANCER RESEARCH

Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells

(2011) J. Faget et al.   CANCER RESEARCH

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies

(2011) L. Apetoh et al.   CURRENT MOLECULAR MEDICINE

IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization

(2011) Kai-ping Han et al.   CYTOKINE

Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma

(2011) L. F. Porrata et al.   HAEMATOLOGICA

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

(2011) Yu Ri Kim et al.   Journal of Hematology & Oncology

Cancer Burden in the HIV-Infected Population in the United States

(2011) Meredith S. Shiels et al.   JNCI-Journal of the National Cancer Institute

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases

(2011) Silvia Novello et al.   Journal of Thoracic Oncology

Pancreatic Cancer Alters Human CD4+ T Lymphocyte Function

(2011) Paola Fogar et al.   PANCREAS

Interleukin-15 biology and its therapeutic implications in cancer

(2011) Jason C. Steel et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

HIV transmission and high rates of late diagnoses among adults aged 50 years and over

(2010) Ruth D Smith et al.   AIDS

Interleukin-7 treatment counteracts IFN-  therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques

(2010) R. Parker et al.   BLOOD

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis

(2010) A Dufresne et al.   BRITISH JOURNAL OF CANCER

Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients

(2010) B. Palermo et al.   CANCER RESEARCH

Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy

(2010) C. Sportes et al.   CLINICAL CANCER RESEARCH

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Severe immunodeficiency in patients treated with fludarabine monophosphate

(2010) P. W. Wijermans et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity

(2010) Thomas R. Malek et al.   IMMUNITY

Increased antigen responsiveness of naive CD8 T cells exposed to IL-7 and IL-21 is associated with decreased CD5 expression

(2010) Julien Gagnon et al.   IMMUNOLOGY AND CELL BIOLOGY

Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified

(2010) Jorge J. Castillo et al.   LEUKEMIA & LYMPHOMA

Pretreatment T Lymphocyte Numbers Are Contributing to the Prognostic Significance of Absolute Lymphocyte Numbers in B-cell Non-Hodgkins Lymphomas

(2010) Lajos Gergely et al.   PATHOLOGY & ONCOLOGY RESEARCH

In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients

(2010) L. Weiss et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

(2009) Benoît Marin et al.   AIDS

A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin  : a prospective randomized controlled trial of the ELYPSE study group

(2009) I. Ray-Coquard et al.   ANNALS OF ONCOLOGY

Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques

(2009) S. Beq et al.   BLOOD

Safety and immunologic effects of IL-15 administration in nonhuman primates

(2009) C. Berger et al.   BLOOD

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection

(2009) I. Sereti et al.   BLOOD

Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome

(2009) C. Menetrier-Caux et al.   CANCER RESEARCH

Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

(2009) Isabelle Ray-Coquard et al.   CANCER RESEARCH

Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

(2009) M. Gobert et al.   CANCER RESEARCH

Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T Cells

(2009) Shomyseh Sanjabi et al.   IMMUNITY

Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression

(2009) Ethan M. Shevach   IMMUNITY

Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression

(2009) Roger J Bedimo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies

(2009) Marc Pellegrini et al.   NATURE MEDICINE

Interleukin-2 Therapy in Patients with HIV Infection

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study

(2008) Hilmi Ege et al.   BRITISH JOURNAL OF HAEMATOLOGY

CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?

(2008) C. Menard et al.   CLINICAL CANCER RESEARCH

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab

(2008) Yasuhiro Oki et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets

(2008) Claude Sportès et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas

(2008) Dipti Talaulikar et al.   LEUKEMIA & LYMPHOMA

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma

(2008) Maria Christina Cox et al.   LEUKEMIA & LYMPHOMA

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA